Biotechnology News XOLAIR Search

BioNews
Biotechnology, Pharmaceutical, Life Science & Medical News
Track this topic with BioWatch News Alerts: Register | Login

Search Results

Documents 1-12 out of 12 found

Current Search: xolair: 12

Genentech Inc (NYSE:DNA) to Release Q2 2008 Earnings July 14
Genentech, Inc.

(NYSE:DNA) will release the second quarter earnings for 2008 on Monday, July 14.

A live webcast with Genentech management will follow the release of the financial results at 1:45 pm PT.

To access the webcast, visit the...

TransWorldNews: Jul 2 2008 6:46AM
Matching: xolair

Find similar documents

Examine the Monoclonal Antibodies Report: 2008 Update
Examine the Monoclonal Antibodies Report: 2008 Update - Detailed analysis of the monoclonal antibody segment, encompassing market dynamics, key therapy areas, technology and target types through to 2013, evaluating the strategies companies...

Canadian Business Magazine: Jun 25 2008 8:31PM
Matching: xolair

Find similar documents

Examine the Monoclonal Antibodies Report: 2008 Update
The report provides a comprehensive financial and strategic analysis of the mAb market, forecasting its commercial evolution out to 2013 and assessing trends by product, company, therapy area, technology and target type.

It also provides...

Street Insider: Jun 25 2008 6:47PM
Matching: xolair

Find similar documents

Foreign Firms To Introduce Major Antibody Drugs In Japan
Novartis' Xolair will be the first antibody asthma drug to be introduced in Japan, with sales slated to start by year's end.

According to the Ministry of Health, there were 1.09 million asthma patients nationwide in 2005, up 2 per...

TradingMarkets: Jun 10 2008 7:21AM
Matching: xolair

Find similar documents

Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (F
SOUTH SAN FRANCISCO, Calif., June 3 (HSMN NewsFeed) -- Sunesis Pharmaceuticals, Inc.

(Nasdaq: SNSS ) today announced the expansion of its late-stage development leadership team with the appointment of industry veterans Steven B.

Ketchum,...

Healthcare Sales & Marketing Network: Jun 6 2008 10:21AM
Matching: xolair

Find similar documents

Antibody drug cost-effective for allergic asthma
NEW YORK (Reuters Health) - The antibody drug omalizumab (Xolair) is cost-effective for treating allergic asthma that has not responded fully to steroid inhalers and other mediations, according to a report in the journal Allergy.

National Post: Jun 4 2008 12:02PM
Matching: xolair

Find similar documents

Antibody drug cost-effective for allergic asthma
Written by: Will Boggs, MD NEW YORK (Reuters Health) - The antibody drug omalizumab (Xolair) is cost-effective for treating allergic asthma that has not responded fully to steroid inhalers and other mediations, according to a report in...

Canada.com: Jun 4 2008 11:36AM
Matching: xolair

Find similar documents

Reuters UK: Jun 4 2008 1:26AM
Matching: xolair

Find similar documents

Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (F
SOUTH SAN FRANCISCO, Calif., June 3 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc.

(Nasdaq: SNSS - News) today announced the expansion of its late-stage development leadership team with the appointment of industry veterans Steven...

PR Newswire via Yahoo!: Jun 3 2008 9:50PM
Matching: xolair

Find similar documents

Micromet Demonstrates that the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can B
- Micromet, Inc.

(Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, presented at the annual meeting of the American Association for Cancer...

HUGIN Online: Apr 14 2008 7:47PM
Matching: xolair

Find similar documents

Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can B
/PRNewswire-FirstCall/ -- Micromet, Inc.

, a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, presented at the annual meeting of the American Association...

Pharma Live: Apr 14 2008 7:57PM
Matching: xolair

Find similar documents

Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can B
BETHESDA, Md., April 14 /PRNewswire-FirstCall/ -- Micromet, Inc.

, a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, presented at the annual meeting of...

Stockwatch: Apr 14 2008 7:05PM
Matching: xolair

Find similar documents

Home Marketing Services News Reports Company Profiles InDepth Drug Discovery Careers Conferences Videos Search Contact
	Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner. See User Agreement Send comments and feedback to: Peter Barfoot Managing Director, BioPortfolio Ltd. UK Tel: (+44) 1300 321501 USA Voicemail and Fax: (+1) 415 680 2472	All rights reserved. All other trademarks recognized. BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10 Copyright � 1997-2008 - BioPortfolio Limited.